Mursla Bio
PrivateLast Round
Convertible Debt
Sep 1, 2020
Total Funding Raised
$602,000
Company Overview
Mursla Bio operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Convertible Debt round in September 2020.
Mursla Bio is a biotechnology company developing a non-invasive diagnostic platform for the early detection of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical AI, Drug Discovery, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Revenue Share, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mursla Bio Comparables
Compare Mursla Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Helio Genomics | 84% | |
| Mercy BioAnalytics | 83% | |
| Glycotest, Inc. | 82% |
For institutional investors. Book with your work email.
Mursla Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Sep 1, 2020 | ||||
| Grant | Sep 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mursla Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Fund | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 99% MoM.
- Mar 26, 2026
Joined the ABHI US Accelerator program to support US market entry.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 26, 2026
At the 18th annual BioUK Awards, BioUK names Mursla Ltd. Best Emerging Biotech Company at an event presented in the United Kingdom on Oct 21st '26.
- attends_eventOct 26, 2026
Mursla Ltd. attends the 18th annual BioUK Awards in United Kingdom on Oct 21st '26, where it is named Best Emerging Biotech Company.
- receives_awardOct 23, 2026
At the 18th annual BioUK Awards in the United Kingdom on Oct 27th '26, BioUK awards Mursla Ltd. the Best Emerging Biotech Company Award, sponsored by Thermo Fisher Scientific, for its leadership in extracellular vesicle science.
For institutional investors. Book with your work email.
Mursla Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mursla Bio's valuation, stock price, and market status.
Is Mursla Bio a public or private company?
Mursla Bio is a private company.
What is the current stock price of Mursla Bio?
Mursla Bio is a private company, so its shares have no public market price. Caplight tracks Mursla Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mursla Bio worth (valuation)?
Valuation information for Mursla Bio is not publicly available.
Can I buy Mursla Bio stock?
Mursla Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mursla Bio's last funding round?
Mursla Bio's most recent funding round was Convertible Debt on September 1, 2020.
Who are the main investors in Mursla Bio?
Key investors in Mursla Bio include Future Fund.
Will Mursla Bio IPO soon?
No public IPO plans have been announced for Mursla Bio.
How can I track Mursla Bio secondary market activity?
Caplight tracks bids, offers, and trades in Mursla Bio's shares on secondary markets.